Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2026 am IST			5-day change	1st Jan Change
30.18 ^USD	+7.29%		+4.79%	-23.71%

10/06	AtriCure, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 08:40 AM
12/05	AtriCure, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

f81a9f0f63d2.S86DDpbIPn4UhQhYil5slXBB1OVdjsVa5nxkegUxE7s.f4jgfqe-bjoi6E9o1Wc95gciuY4ot4Nsgx8qO1F6Uegkg9w35vlEJiD0fw~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

18/02	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
18/02	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
12/02	AtriCure Shares Fall After JPMorgan Downgrade	MT
12/02	Top Midday Decliners	MT
11/02	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
30/25/30	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
30/25/30	AtriCure Q2 revenue beats estimates	RE
30/25/30	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
28/25/28	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
13/25/13	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
30/24/30	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
31/24/31	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
02/24/02	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
23/24/23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
16/24/16	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
16/24/16	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
16/24/16	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
22/24/22	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23/23/23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
29/23/29	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
26/23/26	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
03/23/03	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
22/23/22	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT
22/23/22	Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	MT
22/23/22	Canaccord Genuity Adjusts Price Target on AtriCure to $74 From $81, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					+55.73%
	ABBOTT LABORATORIES					+23.82%
	MEDTRONIC PLC					+21.02%
	CENCORA, INC.					+22.67%
	HOYA CORPORATION					+18.79%
	BECTON, DICKINSON AND COMPANY					+14%
	MEDLINE INC.					+31.59%
	DEXCOM, INC.					+21.53%
	WEST PHARMACEUTICAL SERVICES, INC.					+2.26%
	STERIS PLC					+19.1%
	Average					+23.05%
	Weighted average by Cap.					+21.10%